TMCnet News
7th Annual Traumatic Brain Injury Conference: Arlington, United States - May 24-25, 2017 - Industry Registration - Research and MarketsResearch and Markets has announced the addition of the "7th Annual Traumatic Brain Injury Conference - Industry" conference to their offering. This event provides a special opportunity for a variety of stakeholders to present original research and analysis aimed at providing a full picture of the progress being made towards better diagnosis, treatment and long-term care for TBI survivors. At this annual event, physicians, nurses, neurosurgeons, scientists, and drug/diagnostic developers from all over the world network and learn from one another. Focus areas include: - Current Clinical Management of TBI - Advances and Opportunities for TBI Biomarkers - Recovery, Regeneration and Plasticity - TBI Therapeutic Preclinical/Clinical Candidates - Outcomes Research - Large-scale Observational Studies of TBI - Neuroimaging Research and Practice - Emerging Tools for Diagnosis/Assessment of TBIs - Preclinical/Clinical Development Models/Design Agenda: MAY 24, 2017 7:45 am Registration/Continental Breakfast 8:25 am Development and Characterization of Preclinical Models of Repetitive mild TBI as a Platform for Therapeutic Target (News - Alert) Identification and Biomarker Discovery 8:50 Presentation 9:15 am NOXious Neuroinflammation: A New Therapeutic Target for Chronic Traumatic Brain Injury 9:40 am Refreshment Break/Scientific Poster Session Viewing 10:10 am Developing a Cognition Endpoint for TBI Clinical Trials 10:35 am Exosomes: Nano-restorative Therapy for the Treatment of Neurological Diseases and Injury 11:00 am VAS203 for Moderate and Severe TBI: From Clinical Phase II to Phase III 11:25 am Phenoxybenzamine as a Neuroprotective Candidate for TBI 11:50 am Clinical Development of Human Mesenchymal Stem Cells (MSCs) for Chronic Neurological Injury - the SanBio Experience 1:15 PANEL SESSION: Milestones and Existing Challenges in Preclinical and Clinical Development of TBI Therapeutics 1:45 pm The Late Effects of TBI Study (LETBI): Overview and Preliminary Findings 2:10 pm The Long-Term Effects of Penetrating and Closed Traumatic Brain Injuries 2:35 pm Comprehensive Longitudinal Analysis of the Causal Pathways for Post Concussion Symptom Reporting in OEF/OIF (News - Alert)/OND Veterans 3:00 pm Refreshment Break/Scientific Poster Session Viewing 3:25 pm PANEL SESSION: The Long-Term Effects of Traumatic Brain Injury 3:55 pm The Canadian Traumatic Brain Injury Research Consortium (CTRC): A Collaborative Research Model 4:25 pm Rehabilitation after Concussion: a Pediatric Experience 4:50 pm Neurobiopsychosocial Model of TBI: Lessons Learned from Sports Concussion Research 5:15 pm Evening Cocktail Reception MAY 25, 2017 7:30 am Continental Breakfast 8:00 am New Frontiers in CNS Biomarkers 8:25 am A Tale of Two Biomarkers - Changing the Paradigm for Concussion Management in the Emergency Department in Children and Adults 8:50 am Circulating Brain Damage Markers for the Diagnosis of Traumatic Brain Injury: the Questions You Never Dared to Ask 9:15 am Blood-Based Biomarkers in the Emergency Room: Utility, Diagnostic Specificity and Costs 9:40 am Refreshment Break/Scientific Poster Session Viewing 10:00 am PANEL SESSION: Trends in Biomarker Development for Traumatic Brain Injury 10:30 am Longitudinal Electrophysiological Signatures of Mild Blast Brain Injury in a Novel Mouse Model 10:55 am Rapid Detection of TBI Biomarkers Using Tbit Nanowire Technology to Reduce Unnecessary Head CT 11:20 am Traumatic Brain Injury Research: Historical and Current Perspectives 11:45 am Presentation Title 12:10 pm Luncheon 1:25 pm Rewiring of the Hippocampus After Exposure to Concussive Blast Injury 1:50 pm Understanding the Complexities of Traumatic Brain Injury: Big Data Approach to Tackle a Big Disease 2:15 PANEL SESSION 2:50 End of Conference For more information about this conference visit http://www.researchandmarkets.com/research/3bjx5d/7th_annual
View source version on businesswire.com: http://www.businesswire.com/news/home/20170323005699/en/ |